This is an old revision of this page, as edited by OAbot (talk | contribs) at 22:18, 31 December 2020 (Open access bot: doi added to citation with #oabot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:18, 31 December 2020 by OAbot (talk | contribs) (Open access bot: doi added to citation with #oabot.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | VAP-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (what is this?) (verify) | |
Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1. Development of the drug was discontinued in 2002.
References
- Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T (June 2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.
- "Vepalimomab". AdisInsight. Springer Nature Switzerland AG.
| Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |